TheraCea marked a significant milestone by participating in the esteemed Destination Startup® 2022 Showcase. This event, an embodiment of collaboration between premier research universities and federal laboratories across the Intermountain West region, serves as a vanguard for our innovation ecosystem. Since its inception in 2019, Destination Startup® has attracted over 600 investors, prominent business figures, and thought leaders from across the nation, fostering invaluable connections. Notably, companies showcased within this platform have collectively secured a remarkable $110 million in venture capital, angel investments, and grant funding. By being part of Destination Startup®, TheraCea not only demonstrates its pioneering spirit but also contributes to the potent synergy between groundbreaking research and impactful business ventures, propelling our mission to reshape the landscape of radiopharmaceuticals and immunotherapy.